Beigene (06160) releases annual performance report for 2024: Total revenue of 27.214 billion yuan, a year-on-year increase of 56.2%.

BEIGENE (06160) released its financial report for the year 2024, with total revenue of 27.214 billion yuan, a year-on-year increase of 56.2%; a net loss attributable to owners of the parent company of 4.978 billion yuan, a year-on-year decrease of 25.87%; and a basic loss per share of 3.64 yuan. The announcement stated that the increase in revenue was mainly driven by the sales growth of Baidu Ze (zebrutinib capsules), as well as the sales growth of licensed products from AstraZeneca and Baize An (temozolomide monoclonal antibody). In 2024, Baidu Ze achieved global sales of 18.859 billion yuan, a year-on-year increase of 106.4%, further consolidating its leading position in the field of hematologic malignancies. Sales in the United States totaled 13.890 billion yuan, a year-on-year increase of 107.5%, driven by increased demand in the indication of chronic lymphocytic leukemia (CLL), primarily due to the product's leadership in the CLL and all other approved indications for new patient treatment in the United States, with continuous market share growth. Sales in Europe totaled 2.564 billion yuan, a year-on-year increase of 195.4%, mainly benefiting from the increase in market share in all major markets, including Germany, Italy, Spain, France, and the United Kingdom. Sales in China totaled 1.856 billion yuan, a year-on-year increase of 35.2%, mainly benefiting from sales growth in approved indications. The company continues to maintain its leading market share in the BTK inhibitor market in China. Currently, Baidu Ze has four approved indications in China included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List" ("National Medical Insurance List"). In 2024, sales of Baize An totaled 4.467 billion yuan, a year-on-year increase of 17.4%. The growth in sales of Baize An is mainly attributed to the increase in demand from new patients brought by the inclusion of new indications in medical insurance and the increase in the number of drug administrations. Baize An has obtained a leading market share in the PD-1 market in China. Currently, Baize An has been approved for 14 indications in China, of which 13 indications that meet the criteria have been included in the National Medical Insurance List.